m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03160
 [1]
Histone modification H3K4me3 KMT2A METTL3 Direct Enhancement m6A modification ATG4a ATG4a METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Cysteine protease ATG4A (ATG4A)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone-lysine N-methyltransferase 2A (KMT2A) WRITER View Details
Regulated Target Histone H3 lysine 4 trimethylation (H3K4me3) View Details
Downstream Gene METTL3 View Details
Crosstalk Relationship Histone modification  →  m6A Enhancement
Crosstalk Mechanism histone modification directly impacts m6A modification through modulating the level of m6A regulator
Crosstalk Summary KMT2A-mediated Histone H3 lysine 4 trimethylation (H3K4me3) regulates the autophagy-GATA4 axis through METTL3-mediated m6A modification of Cysteine protease ATG4A (ATG4A) in a YTHDF2 dependent manner to promote NPCs senescence and IVDD progression
Responsed Disease Intervertebral disc degeneration ICD-11: FA80
 Disease Info 
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
FA80: Intervertebral disc degeneration 3 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Rexlemestrocel-L Phase 3 [2]
Synonyms
MPC-150-M
    Click to Show/Hide
External Link
TTD: DHV2L8
 Compound Name CybroCell Phase 1/2 [3]
External Link
TTD: DS6C1Y
 Compound Name IDCT Phase 1/2 [4]
Synonyms
rebonuputemcel
    Click to Show/Hide
External Link
TTD: DK65RJ
References
Ref 1 KMT2A regulates the autophagy-GATA4 axis through METTL3-mediated m(6)A modification of ATG4a to promote NPCs senescence and IVDD progression. Bone Res. 2024 Nov 21;12(1):67. doi: 10.1038/s41413-024-00373-1.
Ref 2 ClinicalTrials.gov (NCT02412735) Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Subjects With Chronic Low Back Pain (MSB-DR003). U.S. National Institutes of Health.
Ref 3 Clinical pipeline report, company report or official report of FibroGenesis.
Ref 4 ClinicalTrials.gov (NCT03955315) Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration. U.S. National Institutes of Health.